SGAs are as clinically effective as FGAs for medical management of psychosis with lower incidences of EPS and hyperprolactinemia, likely because SGAs occupy less than 60% of striatal DRD2 (as opposed to FGAs, which can occupy 65%) and/or the faster dissociation from DRD2 binding sites [1]. Here, DRD2 is linked to hyperprolactinemia.